About the VISTA clinical study

The VISTA clinical study will assess whether an investigational drug (potential new treatment) can reduce delusions or hallucinations in people with Alzheimer’s disease.

If you (or your loved one) decide to take part, the study will last about 13 weeks and will include about 7 visits to the study clinic.

This will include:

• A Screening Period of up to 35 days (to assess whether study participation is right for you)
• A Treatment Period of approximately 7 weeks, where you will take the investigational drug or a placebo* by mouth twice daily
• A Safety Follow-up Period, approximately 1 week after your last dose of study treatment

*A placebo is an inactive pill that looks the same as the investigational drug but does not contain any active ingredient. Researchers use placebos to ensure any effects seen in the study are due to the investigational drug. Participants will have a 50% chance of being assigned to receive either the investigational drug or the placebo.

Throughout the clinical study, a team of doctors, researchers and healthcare professionals will provide medical oversight and check on your progress.

Participants who complete this study may have the option to enroll in a year-long extension study, if they are eligible. All participants in the extension will receive the investigational drug (there will be no placebo group).

What is an investigational drug?

Investigational drugs are potential medications that are still being studied and have not yet undergone all the necessary stages of drug development. Investigational drugs cannot be approved for human use until clinical studies, like the VISTA clinical study, have collected enough data to demonstrate that they are safe and effective.

The investigational drug in this study is thought to regulate parts of the brain involved in hallucinations and delusions (psychosis)¹.

The investigational drug in this study has not been approved to treat people with Alzheimer’s disease or any other condition.